Incannex Healthcare is investigating psilocybin in combination with psychotherapy for Generalized Anxiety Disorder.
CLINICAL TRIALS: Yes.
Clinical trials address the following disorders: Obstructive sleep apnea, pulmonary inflammation, rheumatoid arthritis, inflammatory bowel disease, lung inflammation, concussion, minor traumatic brain injury as well as nausea and vomiting in chemotherapy.
OWNERSHIP:
APIRx Pharmaceutical USA is a leading pharmaceutical company specialized in cannabinoid active pharmaceutical ingredients and drug products. They have 19 granted patents with several of them being for chewable tablets or chewing gum for cannabis dependence, nicotine addiction as well as opioid addiction, and over 20 pending patents.
Psychennex is in charge of Clarion Clinics which was the first dedicated psychedelic-assisted psychotherapy business in Australia opening a clinic in Melbourne. The company has a partnership with one of Australia’s leading clinical psychedelic professionals. The aim of the company is to open up 10 owned clinics as well as having a goal of opening 80+ clinics with the help of franchise and licensed business models.
PRODUCTS:
CannQuit-N combines nicotine and CBD within a controlled-release, functional, medicated chewing gum developed to assist addicted smokers to quit smoking.
CannQuit-O is a patented chewing gum that combines cannabinoids with opioid agonists and/or antagonists developed to combat opioid addiction.
MedChew Rx with CBD & THC is a gum used for pain and spasticity in multiple sclerosis and contains the same constituents as Sativex but dosing is extended, reducing the need to re-administer up to 12 times per day and does not contain alcohol.
FACILITIES:
The company has a lease in Melbourne planned for the opening of a psychedelic-assisted psychotherapy clinic, plans are to open several more in Australia and abroad in the future.
NEWS & PARTNERSHIPS:
2021
The company made a deal with Vectura to develop the drug formulation for IHL-216A to be used in clinical trials.
IHL-216A is being researched in a partnership with the Trauma Group of Monash University’s Department of Neuroscience whom are using a model devised in partnership with the NFL. As part of the Monash Trauma Group study, the team will test the effectiveness of IHL-216A against isolated agents including CBD and isoflurane. Using the model developed by the NFL, the study will replicate the collision mechanics of sports-related concussions, scaled at a level for lab rodents.
2022
The company made a deal with Eurofins for the manufacture of ReneCann which is IHL’s proprietary topical cannabinoid formulation including CBG and CBD. for treatment of skin conditions caused by disorders of the immune system, including vitiligo, psoriasis, and atopic dermatitis.
The company made another deal with Eurofins to formulate and manufacture two novel addiction treatments in a chewable form called CannQuit-N and CannQuit-O that are made for helping people with opioid and nicotine addiction disorders.
The company made a deal with Curia to further develop and manufacture its proprietary inhaled drug product IHL-216A for the treatment of concussion and traumatic brain injury.
The company and Monash University collaborates on ground-breaking research to advance treatment for severe forms of anxiety disorders using virtual reality combined with psychedelics with the goal of developing a novel treatment with a combination of VR and psychedelics. The company was given a global, exclusive license in perpetuity for an immersive therapeutic VR environment developed by BrainPark, a state-of-the-art clinical research platform at Monash University’s Turner Institute for Brain and Mental Health.
2023
Incannex partnered with Catalent to manufacture psilocybin. Catalent will formulate and manufacture the drug for use in clinical trials with cGMP regulations. The manufacturing process will be scalable into commercial-scale levels if needed.
Incannex Healthcare contracted PharmAla Biotech to supply clinical-grade MDMA and psilocybin for clinical operations.